October 6, 2025 |
Medscape Oncology will be pioneering pathways at the 2025 ESMO congress taking place in Berlin, Germany this October.

The team will be hosting 5 dynamic satellite symposia at the congress on topics including advances in metastatic breast cancer, personalizing care for prostate cancer, HER2-targeted therapy for gynecologic cancers, and other important topics in oncology. These symposia are designed to engage clinician learners and help them translate the latest data into action through downloadable slides and lively conversation between world-renowned experts. More information on the symposia and links to register are available here.
We invite Congress attendees to stop by the Medscape booth (#1009) in the exhibit hall to connect with the Medscape Oncology team and explore our latest innovations in oncology education, including the launch of the PIONEER Learning Center – PrecIsion Oncology: Navigating EvidEnce for Real-world impact.
“We have very exciting new education in topics like precision oncology that are going to help learners advance their care and reach more patients. We’re looking forward to great meetings and conversations with our oncology colleagues while we’re in Berlin so we can share more about it,” said Zhizhi Fiske
The Medscape team will be attending the congress from 17-20 October.
For more information on Medscape Oncology education, please contact Zhizhi Fiske
About Medscape Education
Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professionals.
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. We are the largest medical education provider, delivering precision education for actionable outcomes across 30+ specialties in…
